PI3K 抑制剂能否解乳腺癌内分泌治疗耐药的燃眉之急？以 PI3K 抑制剂为基础的联合治疗对于内分泌耐药人群的治疗前景如何？本文中，笔者与您一同来探讨这些问题，旨在为临床诊疗提供思路与启发。

中国医药卫生事业发展基金会乳腺肿瘤学组启动会于2025年3月1日在广州举行，雅康博董事长许军普、联席总裁张学华、副总裁付原等一行高管团队代表雅康博，作为支持方出席了本次活动。 中国医药卫生事业发展基金会是一家致力于推动中国医药卫生事业进步的 ...

乳腺癌是女性中最常见的癌症类型，全球每年确诊超过200万例，2020年中国的新发病例约42万，HR+乳腺癌亚型约占所有乳腺癌的70%，患者基数十分庞大。

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression, metabolic ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

The review highlights next-generation therapies that specifically target PIK3CA mutations with improved selectivity and reduced toxicity. Several promising inhibitors, including RLY-2608, STX-478 ...

新京报讯（记者王卡拉）3月14日，国家药品监督管理局官网发布公告，通过优先审评审批程序批准Roche Pharma (Schweiz) AG申报的1类创新药伊那利塞片 ...

A newly published review in Genes & Diseases explores the oncogenic activation of PIK3CA in cancer and highlights emerging targeted therapies designed to improve treatment efficacy while reducing side ...